Literature DB >> 15539894

Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial.

J-P Ortonne1, R Kaufmann, M Lecha, M Goodfield.   

Abstract

BACKGROUND: A two-compound product containing calcipotriol 50 microg/g and betamethasone dipropionate 0.5 mg/g (Daivobet, Dovobet) has been demonstrated to be an effective, once daily, treatment for psoriasis vulgaris.
OBJECTIVE: To compare the efficacy and safety of treatment with the two-compound product for 4 weeks followed by calcipotriol for 4 weeks, with that of tacalcitol for 8 weeks in patients with stable psoriasis vulgaris.
METHODS: 501 patients were randomised to double-blind treatment with the two-compound product followed by calcipotriol 50 microg/g once daily, or to tacalcitol 4 microg/g once daily.
RESULTS: Treatment with the two-compound product/calcipotriol was significantly more effective than tacalcitol in terms of mean percentage PASI reduction (65.0 vs. 33.3% at week 4 and 59.0 vs. 38.4% at week 8; p < 0.001 for both).
CONCLUSION: A treatment regimen comprising calcipotriol/betamethasone ointment (Daivobet) for 4 weeks followed by calcipotriol for 4 weeks is superior to tacalcitol ointment for 8 weeks in patients with psoriasis vulgaris. Copyright (c) 2004 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15539894     DOI: 10.1159/000080854

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  5 in total

Review 1.  Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris of the trunk, limbs and scalp.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2011-04-16       Impact factor: 9.546

2.  Treatment of psoriasis vulgaris with the two-compound product calcipotriol/betamethasone dipropionate followed by different formulations of calcipotriol.

Authors:  Nicoletta Cassano; Antonio Miracapillo; Carmela Coviello; Francesco Loconsole; Marco Bellino; Gino Antonio Vena
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

3.  Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris.

Authors:  Efstratios Vakirlis; Athanasios Kastanis; Demetrios Ioannides
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423

Review 4.  German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version).

Authors:  A Nast; I Kopp; M Augustin; K B Banditt; W H Boehncke; M Follmann; M Friedrich; M Huber; C Kahl; J Klaus; J Koza; I Kreiselmaier; J Mohr; U Mrowietz; H M Ockenfels; H D Orzechowski; J Prinz; K Reich; T Rosenbach; S Rosumeck; M Schlaeger; G Schmid-Ott; M Sebastian; V Streit; T Weberschock; B Rzany
Journal:  Arch Dermatol Res       Date:  2007-05-12       Impact factor: 3.017

Review 5.  Calcipotriol/betamethasone for the treatment of psoriasis: efficacy, safety, and patient acceptability.

Authors:  Christina Rogalski
Journal:  Psoriasis (Auckl)       Date:  2015-06-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.